Bill
SB 410
New Mexico bill would reschedule crystalline polymorph psilocybin from Schedule I, potentially enabling medical research but creating federal-state drug policy conflict.
SB 410 would reschedule crystalline polymorph psilocybin from a Schedule I controlled substance to a different legal classification in New Mexico. This targets a specific chemical form of psilocybin rather than psilocybin broadly, potentially creating a regulatory pathway for research or therapeutic use of this particular variant.
Psilocybin rescheduling could enable clinical research into its potential therapeutic applications for mental health conditions like depression, PTSD, and end-of-life anxiety—areas where early research shows promise. However, this also represents a significant departure from federal drug policy and raises questions about state-level drug scheduling authority and implementation challenges.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
